Gary Clark: Unfiltered

The American Academy of Pediatrics is plugging its gold-standard guidance into an AI brain. It’s a move set to transform pediatric care and a major test for AI.

A new bispecific antibody from Kelun-Biotech and Harbour BioMed just got a green light in China, promising quarterly doses for asthma. Is this the innovation that finally unseats the market giants?

Mesabi Trust's drastic 58% distribution cut reveals more than just lower royalties. It's a stark warning about market volatility and Cleveland-Cliffs' strategy.

A federal judge sanctions top DOJ officials over a 'collusive' $1.8B Trump settlement, exposing a brazen attempt to subvert the law for political gain.

Silverstein Properties is now offering AI-powered workplace analytics as an amenity. This isn't just a perk; it's a structural shift in real estate value.

Godspeed Capital's ICE USA platform acquires a key land acquisition firm, a strategic move to create a one-stop-shop for booming public works projects.

German fintech Pliant enters the crowded U.S. market, challenging giants like Ramp and Brex. Is its API-first infrastructure model the key to winning?

With ASTM approval secured and mandates looming, Argus Media's new methanol-to-jet index provides the pricing transparency needed to fuel aviation's costly green transition.

As HESM preps its Q2 earnings call, the market is watching. Beyond the numbers, it's a test of its fee-based model against Bakken's pulse.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

A rare mid-year IRS mileage rate hike to 76 cents isn't just about gas prices. It's a signal of persistent volatility forcing a strategic rethink.

Comvest Private Equity is now Vesterra Capital Partners. This isn't a pivot, but a strategic sharpening of its operational playbook in a crowded market.

With a $150M war chest, Wire 3 is challenging broadband giants in Florida. Is their 10-gigabit fiber gambit a true game-changer or just another headline?

A biotech's preclinical success in treating miscarriage is just the start. The real story is its strategy of using pregnancy immunology to target cancer.

Sivers Semiconductors pushed its earnings dates. This isn't a sign of trouble; it's the steep cost of admission to Wall Street's premier league.

A new report reveals libraries are the primary defense against digital illiteracy, but they're fighting an uphill battle with limited resources. What's the cost?

A new partnership aims to turn saliva into a data-rich asset, signaling a major shift in the health tech market from reactive treatment to proactive care.

In a crowded market, independent validation is the new currency. Vida Health’s DiMe Seal signals a major shift from marketing hype to proven results.

ES Foundry's 3 GW expansion in South Carolina isn't just another announcement. It's a story of execution, tackling the critical solar cell gap in the US supply chain.

Electra Battery Materials is tapping the markets to fund its critical cobalt refinery, but at what cost? A look at the story behind the numbers.